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Abstract. Background: Nitric oxide (NO) and cholecystokinin
(CCK) are involved in the modulation of several
neurotransmitter systems in the basal ganglia, and a functional
interaction between their modulatory effects could be
hypothesised. Materials and Methods: We studied the effects
exerted by the administration of 7-nitroindazole (7-NI) (50 mg
kg-1 i.p.), a selective inhibitor of neuronal NO synthase, on the
depth EEG activity of the striatum and of the globus pallidus
in both not pre-treated and sulphated CCK octapeptide (CCK-
8S)-treated (100 nM kg-1 i.p.) rats. Striatal and pallidal depth
EEG power spectra were examined by means of a Fast Fourier
Transform analysis. Results: Striatal depth recordings showed
a marked increase of % power of slow standard rhythms after
7-NI systemic treatment. In contrast, pallidal recordings
revealed an increase of % power of rapid standard rhythms
after i.p. injection of 7-NI. The same modifications were not
evidenced in CCK-8S pre-treated rats after 7-NI administration.
Conclusion: The results show an influence exerted by peripheral
CCK on the nitrergic modulation of the bioelectric activities of
the striatum and of the globus pallidus. This effect could be of
particular interest in the light of NO and CCK involvement in
the neuroprotective mechanisms.
The presence of diffusible nitric oxide (NO) (1) has been
largely shown in the context of the central nervous system
(CNS). In fact, it plays a key role in the modulation of
several neurotransmitters, particularly on the excitatory
glutamate and on the inhibitory GABA (2, 3). Moreover,
several lines of evidence have demonstrated that NO is
involved in NMDA-receptor-mediated neurotoxicity in
different areas of the CNS (4-6). In particular, NO synthase
(NOS), activated by Ca2+ influx, produces the neurotoxic
peroxynitrite (ONOO-), through a reaction with superoxide
anion (O2
.-) (7). On the other hand, NO is also considered
to exert an efficacious neuroprotective role through a down-
regulatory effect on the redox site of the NMDA receptor
complex during all the conditions associated with an
overstimulation of NMDA receptors (8). In previous studies,
we explored the role of NO in the modulation of the normal
bioelectric activity of cortical (9) and subcortical (10, 11)
structures, as well as the induction of hyperactivity
phenomena due to a significant reduction of NO cerebral
levels (12, 13). In the CNS, the gastrointestinal peptide
cholecystokinin (CCK) exerts a well known neuro-
modulatory action which shares several analogies with the
NO system (14, 15). In particular, CCK binds two receptor
subtypes: CCK-A, particularly abundant in the
gastrointestinal tract and CCK-B, highlighted in the brain
(16). Interestingly, the peripheral administration of
sulphated cholecystokinin octapeptide (CCK-8S) is able to
influence the activity of several areas in the brain,
particularly in the basal ganglia (17-21). In fact, systemic
CCK-8S crosses the blood-brain barrier (22, 23) and it can
directly interact with several CNS areas (24, 25). At the
same time, it has been demonstrated that peripheral CCK
injection exerts an indirect regulatory influence on CNS
areas, modulating other neurotransmitter systems such as
glutamate, dopamine, GABA, serotonin etc. through the
functional involvement of vagal afferents (26-29). 
A wide range of actions have been proposed for CCK
in various areas of the CNS. In particular, a significant
role of the systemic administration of CCK was
evidenced in modulating both hyperactivity phenomena
and the dopaminergic output from the midbrain, which
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is able to strongly influence the bioelectric activity of
neural structures belonging to the basal ganglia system
(18, 24, 30, 31).
In this study, we aimed to verify whether systemic CCK
pre-treatment influences the functional response of the
striatum and of the globus pallidus to the decrease of 
NO levels obtained by means of systemic injection of 
7-nitroindazole (7-NI). This selective neuronal NOS
inhibitor was administered in order to decrease cerebral NO
levels, while excluding possible side-effects due to the
alterations of cerebral blood flow (28, 32-34). Power spectra
analysis was used to quantitatively describe the effects of the
nNOS inhibition on striatal and pallidal depth EEG activity
in not pre-treated and CCK-8S pre-treated rats. 
Materials and Methods 
Thirty adult male Wistar rats, weighing 220-280 g, were
anaesthetised with urethane (1.2-1.4 g kg-1 intraperitoneally – i.p.).
The trachea was cannulated and the skull exposed. The animals
were positioned in a stereotaxic apparatus (David Kopf
Instruments, USA) and the body temperature was maintained at
37-38ÆC using a heating pad. Heart rate and pupil diameter were
monitored during all the experimental sessions. After the
craniotomy, depth bioelectric activities from both the striatum and
the globus pallidus were simultaneously recorded through stainless-
steel coaxial bipolar electrodes (external diameter 0.5 mm; exposed
tip 25-50 Ìm) inserted into the two structures according to the
stereotaxic co-ordinates of the Atlas of Paxinos and Watson (35);
(Striatum: 8.7-7.2 mm anterior to the interaural line; 6.0-5.0 mm
dorsal to it and 3.5-4.5 mm lateral to the midline. Globus pallidus:
8.0-7.6 mm anterior to the interaural line; 4.0-5.0 mm dorsal to it
and 3.0-3.5 mm lateral to the midline). The bioelectric activity of
the structures examined was amplified, recorded and printed
through an eight-channel polygraph Grass model 7B. The time
constant was set at 0.04 sec and high frequency filters were set at <
30 Hz. Depth striatal and pallidal recordings were time aligned,
such that each pharmacological treatment was preceded by a
control epoch of 15 min and followed by 120 min of recovery
period. EEG spectral quantification was accomplished using Fast
Fourier Transforms (FFTs) algorithms on contiguous 15-min
epochs of unprocessed data (sampling rate: 1024 Hz for each
recording channel), through a software package provided by
DataWave Technologies (Longmont, CO, USA). Spectral power
from 1 to 30 Hz was determined at 1-Hz increments. Power in each
of the four conventional frequency bands (delta, 1-4 Hz; theta, 4-8
Hz; alpha, 8-13 Hz; beta, 13-30 Hz) was expressed as percentage
(%) of the total power in the epoch. The study was performed on
four groups of animals: A) control, not pre-treated (n=5); B)
control, CCK-8S pre-treated (n=5); C) not pre-treated (n=10) and
D) CCK-8S-pre-treated (n=10). In both the C and D groups, 7-
Nitroindazole (7-NI), a selective inhibitor of nNOS, suspended in a
10% aqueous solution of Tween 80 (non-ionic tensioactive agent),
was administered by i.p. injection in a volume of 1 ml/100 g body
weight (vehicle) at the dose of 50 mg kg-1, which causes the
maximal inhibition of nNOS (33). Thirty minutes before 7-NI
administration, the D group of animals received an i.p. injection of
CCK-8S (100 nM kg-1; injection volume 1-2 ml of saline). Control
animals in group A, after 120 min of recording, received an i.p.
injection of the vehicle. Animals in group B, after an observation
period of 120 min, received i.p. CCK-8S at the same dose of the D
group. Both CCK-8S and 7-NI were purchased from Sigma
Chemical Co. (Sigma, St. Louis, MO, USA). 
For each EEG frequency band mean±SD % power values were
compared across recording epochs, before and after drug
treatment, by using one-way analysis of variance (ANOVA) for
repeated measures and the Bonferroni post hoc test. Differences
were considered to be significant at the level of p<0.05. 
At the end of each experiment, the animals were killed with an
overdose of pentobarbital and perfused with 10% buffered
formalin. The brains were removed for histological examination:
serial coronal sections were cut at 30-50 Ìm and stained by using
Nissl thyonine and/or Nissl cresyl violet methods. All animal use
procedures were in strict accordance with European Communities
Council Directive (86/609/EEC) and the Italian Health Ministry
guidelines (D.L. 116/1992) associated with the Animals Scientific
Procedures Act 1986. All efforts were made to minimise the
number of animals employed and to reduce their suffering.
Results
Depth EEG power spectra during the initial observation
period (about 120 min) did not show any significant
difference in the four groups examined. Moreover, the i.p.
injection of the vehicle (group A) did not show alterations
of striatal or pallidal EEG patterns during a further 120
min. Animals in the B group showed no modifications in the
striatal and pallidal depth EEG within 120 min following
CCK-8S i.p. injection. Table I shows the basal values of
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Table I. Basal values of striatal and pallidal EEG power.
Not pre-treated (Group C) CCK-8S pre-treated (Group D)
EEG bands 1-4 Hz 4-8 Hz 8-13 Hz 13-30 Hz 1-4 Hz 4-8 Hz 8-13 Hz 13-30 Hz
Striatum 37.2±9.6 44.3±6.4 11.9±4.3 5.1±1.1 36.9±8.7 45.3±5.9 12.3±5.2 6.4±1.9
GP 38.4±22.6 48.0±23.9 7.6±0.1 4.5±1.8 39.0±17.1 48.8±25.0 6.5±3.3 4.7±1.3
Relative EEG power (mean ± SD) expressed as the % between a single frequency band and the total power values in the striatum and globus
pallidus (GP) before 7-NI i.p. treatment in animals belonging to C and D groups.
striatal and pallidal % EEG total power for each frequency
band in the C and D groups of animals. In particular, in
both basal recordings a more marked % presence of the
delta and theta frequency bands was observed. Figure 1
shows a schematic reconstruction of recording electrode
positions and representative EEG traces before and after
7NI treatment. 
Time course of 1-4 Hz (delta) band % power. Figure 2 reports
the % mean variations of delta band power values recorded
from the striatum and the globus pallidus after i.p. treatment
with 7-NI. An increase of % spectral values in the striatum and
a decrease in the globus pallidus was observed; the maximum
effect was evidenced 90 min after drug administration in the
striatum (+ 39.09 %; F1,8=1251.01, p<0.001) (Figure 2). On
the contrary, the pallidal delta showed a significant decrease
30 min after 7-NI administration (- 8.13 %; F1,8=8.22, p<0.05),
followed by an increase which did not reach the level of
significance (Figure 2). 
CCK-8S pre-treated animals (Group D), when i.p. injected
with 7-NI, did not show any sort of modification within the
delta band recorded from the structures studied throughout
the observation period (about 120 min) (Figure 2).
Time course of 4-8 Hz (theta) band % power. In this frequency
band comparisons between pre- and post 7-NI treatment
values showed a significant decrease of % spectral values in
the striatum and an increase in the globus pallidus. The major
efficacy of the cited modifications was highlighted 90 min
after drug administration in the striatum (-19%; F1,8=149.68,
p<0.001) (Figure 3). In the globus pallidus, theta showed a
significant increase (+8.07%; F1,8=13.39, p<0.01) 30 min
after 7-NI administration (Figure 3). 
In the animals pre-treated with CCK-8S (Group D), the
i.p. injection of 7-NI failed to induce significant
modifications within the theta frequency band in the
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Figure 1. Recording sites and depth EEG. A: schematic serial
reconstruction of depth recording sites within striatum and globus pallidus
in three stereotaxic planes (IL: interaural line). B: representative example
of striatal and pallidal depth bioelectric activity in basal conditions (trace
1) and after 7-NI i.p. administration (50 mg kg-1) (trace 2) in not pre-
treated rats; trace 3 shows the EEG activity after 7-NI treatment in CCK-
8S pre-treated. 
Figure 2. Drug-induced effects on 1-4 Hz band. Time course of %
variations of EEG power in the 1-4 Hz band recorded from the striatum
and the globus pallidus after 7-NI i.p. administration (50 mg kg-1) in not
pre-treated (n=10, left) and CCK-8S pre-treated rats (n = 10, right).
Intervals of 15 min are reported in the abscissa axis. The horizontal line
represents the control reference (100%). *p<0.05, ***p<0.001.
striatum and in the globus pallidus during the total period
of analysis (about 120 min) (Figure 3).
Time course of 8-13 Hz (alpha) band % power. A significant
decrease of % spectral values with a peak at 90 min was
observed after drug administration in the striatum (-29.3%;
F1,8=89.58, p<0.001) (Figure 4). In the globus pallidus an
initial not significant decrease, followed by a significant
increase (+55.58%; F1-8=13.39, p<0.01) 60 min after 7-NI
administration, was observed (Figure 4). 
In the striatum and in the globus pallidus of CCK-8S pre-
treated rats (Group D), no significant modifications within
the alpha frequency band were noted during all the
observation period (about 120 min) (Figure 4).
Time course of 13-30 Hz (beta) band % power. Comparisons
between pre- and post 7-NI treatment showed a significant
decrease of % spectral values in the striatum, with a peak 105
min after drug administration (-27.26%; F1,8=51.47, p<0.001)
(Figure 5). In the globus pallidus an initial decrease was
followed by a significant increase, with a maximum 75 min after
7-NI administration (+27.82%; F1,8=6.94, p<0.05) (Figure 5). 
The pharmacological treatment with i.p. 7-NI in the group
of animals pre-treated with CCK-8S (Group D) did not
induce any sort of significant modifications within the beta
frequency band in the striatum and globus pallidus throughout
the experimental session (about 120 min) (Figure 5).
All 7-NI-induced modifications of % spectral frequency
band were reversible within about 120 min. 
Discussion
In different areas of the CNS, NO is able to influence the
neuronal excitability by modulating two opposite
neurotransmitter systems, such as inhibitory-GABA or
excitatory-glutamate. In the striatum and in the globus
pallidus the functional involvement of NO neurotransmission
in the integrative processes of the motor function has been
highlighted (15, 36). In particular, striatal NOS interneurons
receive convergent information from cortical, pallidal and
nigral afferents, significantly influencing the striatal
GABAergic output (37).
Furthermore, the cortico-striatal glutamatergic projections
and the striato-pallidal GABAergic transmission are also
in vivo 18: 317-324 (2004)
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Figure 3. Drug-induced effects on 4-8 Hz band. Time course of %
variations of EEG power in the 4-8 Hz band recorded from the striatum
and the globus pallidus after 7-NI i.p. administration (50 mg kg-1) in not
pre-treated (n=10, left) and CCK-8S pre-treated rats (n=10, right). Intervals
of 15 min are reported in the abscissa axis. The horizontal line represents
the control reference (100%). *p<0.05, ** p<0.01, *** p<0.001.
Figure 4. Drug-induced effects on 8-12 Hz band. Time course of %
variations of EEG power in the 8-13 Hz band recorded from the striatum
and the globus pallidus after 7-NI i.p. administration (50 mg kg-1) in not
pre-treated (n=10, left) and CCK-8S pre-treated rats (n=10, right). Intervals
of 15 min are reported in the abscissa axis. The horizontal line represents
the control reference (100%). *p<0.05; **p<0.01, ***p<0.001.
under the functional modulation of the CCK, whose
presence has been largely demonstrated by using
immunohistochemical techniques (20, 29). 
The functional mechanisms of the CCK modulation are
not well understood yet: on one hand, central CCK is able
to influence the neuronal excitability by acting on
glutamatergic neurotransmitter systems (38, 39); on the
other hand, systemically administered CCK is able to
modulate different neurotransmitter systems (e.g. glutamate,
GABA, dopamine). 
Taking into consideration the contiguity and the shared
features of CCK and NO neurotransmission, in this study
we verified the possible influence of both neuromodulatory
systems on the bioelectric activity of the corpus striatum and
globus pallidus. In the striatum, 7-NI treatment caused an
increase of the % power in the delta band, while the power
in the other bands was significantly decreased. Previous
results from our laboratory showed a strong excitatory
action of 7-NI on the firing of striatal projection neurons,
without a direct influence on the interneuronal population
(10, 11). The transition from a basal condition, in which
striatal projection neurons are silent or show a sporadic
random firing activity (40), to a new condition, in which they
are recruited to fire, could explain the 7-NI-induced
synchronising effect. 
In the globus pallidus, after 7-NI treatment, the %
power of the delta band was significantly decreased, while
the % power of the theta, alpha and beta bands was
significantly increased. In particular, the alpha and beta
bands showed an early decrease followed by a wide
increase centred at 60-75 min after drug injection. Our
previous results have shown a direct effect of NOS
inhibition on pallidal neurons (41); this influence could
explain the present findings. Nevertheless, the evidence of
a close temporal relationship between striatal EEG de-
synchronisation and pallidal synchronisation suggests a
possible parallel indirect influence exerted by the
activation of the striatal output. 
In the CCK-8S pre–treated rats, 7-NI administration
failed to significantly modify the % power of EEG bands in
both structures. Pre-treatment with CCK-8S increases
central GABA and dopamine (19, 21, 42) and can decrease
the responsiveness of striatal output neurons, counteracting
the effect of NOS inhibition with a following influence of
the globus pallidus activity. The results suggest a functional
co-operation between CCK and NO, probably through the
involvement of other neurotransmitters (e.g. GABA and
dopamine) in the functional balance between the striatal
NOS interneurons and the striato-pallidal projecting
neurones (26, 29, 43). 
NO and CCK could exert an analogous co-operative
effect in terms of neuroprotection in several pathological
events. In fact, the inhibition of neuronal NOS causes an
increase of neuronal excitability up to the appearance of
an epileptiform hyperactivity (3, 12, 44, 45). Furthermore,
CCK exerts a protective action in the neurotoxicity
phenomena associated with trauma (45) and its profile is
down-regulated in different models of epilepsy (31, 46).
Interestingly, peripheral CCK administration enhances
endogenous NGF levels in the brain (47, 48). The
increased availability of NGF causes a stimulatory effect
of neuronal NOS synthesis, reducing, through a regulatory
feedback loop, the effects of the inhibition of neuronal
NOS activity (49-52).
In conclusion, our data suggest a functional interaction
between the CCK and NO systems, which could influence
the intrinsic and the reciprocal activity of the striatum and
of the globus pallidus.
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Figure 5. Drug-induced effects on 13-30 Hz band. Time course of %
variations of EEG power in the 13-30 Hz band recorded from the striatum
and the globus pallidus after 7-NI i.p. administration (50 mg kg-1) in not
pre-treated (n=10, left) and CCK-8S pre-treated rats (n=10, right).
Intervals of 15 min are reported in the abscissa axis. The horizontal line
represents the control reference (100%). *p<0.05, **p<0.01, *** p<0.001. 
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